Technology evaluation: PK1, Pfizer/Cancer Research UK.

Abstract

Pfizer (formerly Pharmacia) is collaborating with Cancer Research UK in developing PK1 (FCE-28068) for the potential treatment of various cancers. PK1 is an N-(2-hydroxypropyl) methacrylamide (HPMA) co-polymer-doxorubicin conjugate, attached by a peptide linker, which is currently undergoing phase II trials for breast, non-small-cell lung and colon cancers.

• Authors: Vladimir Bilim
• Journal: Current opinion in molecular therapeutics (Curr Opin Mol Ther) Vol. 5 Issue 3 Pg. 326-30 (Jun 2003) ISSN: 1464-8431 [Print] England
• PMID: 12870445 (Publication Type: Evaluation Study, Journal Article)

Chemical References

• Acrylamides
• Antineoplastic Agents
• Prodrugs
• N-(2-hydroxypropyl)methacrylamide co-polymer-doxorubicin conjugate
• Doxorubicin
• Glucose

Topics

• Acrylamides (adverse effects, metabolism, pharmacology, therapeutic use)
• Animals
• Antineoplastic Agents (adverse effects, metabolism, pharmacology, therapeutic use)
• Clinical Trials, Phase I as Topic
• Clinical Trials, Phase II as Topic
• Doxorubicin (adverse effects, metabolism, pharmacology, therapeutic use)
• Drug Delivery Systems
• Glucose (adverse effects, metabolism, pharmacology)
• Humans
• Neoplasms (drug therapy)
• Prodrugs (metabolism)